Searchable abstracts of presentations at key conferences in endocrinology

ea0092op-13-04 | Oral Session 13: Pathophysiological actions of thyroid hormones | ETA2023

Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors

Porcelli Tommaso , Ambrosio Raffaele , Angela De Stefano Maria , Luongo Cristina , Miro Caterina , Dentice Monica , Schlumberger Martin , Salvatore Domenico

Purpose: Treatment with tyrosine kinase inhibitors (TKI) has been associated with alterations in circulating thyroid hormone levels, possibly related to perturbations in peripheral thyroid hormone metabolism. In this study, we evaluated the effect of the multi-kinase inhibitor vandetanib on the expression of the three deiodinase selenoenzymes.Materials and Methods: Cell models that endogenously express either D1 (HepG2 and HEK-293), D2 (HeLa and KMH-2) o...

ea0092ps2-19-04 | Thyroid Hormone Transport & Metabolism Basic | ETA2023

Repositioning of cefuroxime as novel selective inhibitor of the thyroid hormone activating enzyme type 2 deiodinase

Miro Caterina , Sagliocchi Serena , Murolo Melania , Gaetana Cicatiello Annunziata , Nappi Annarita , Di Cicco Emery , Torabinejad Sepehr , Dentice Monica

The iodothyronine deiodinases constitute a family of three selenoenzymes regulating the intracellular metabolism of Thyroid Hormones (THs, T4 and T3) and impacting on several physiological processes, including energy metabolism, development and cell differentiation. The type 1, 2 and 3 deiodinases (D1, D2, and D3), are sensitive, rate-limiting components within the TH axis, and rapidly control TH action in physiological conditions or disease. Notably, several human pathologies...